Directive 1989/105 - Transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems

Please note

This page contains a limited version of this dossier in the EU Monitor.

1.

Current status

This directive has been published on February 11, 1989, entered into force on December 27, 1988 and should have been implemented in national regulation on December 31, 1989 at the latest.

2.

Key information

official title

Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems
 
Legal instrument Directive
Number legal act Directive 1989/105
Original proposal COM(1988)231
CELEX number i 31989L0105

3.

Key dates

Document 21-12-1988
Publication in Official Journal 11-02-1989; Special edition in Latvian: Chapter 05 Volume 001,Special edition in Estonian: Chapter 05 Volume 001,Special edition in Romanian: Chapter 05 Volume 002,Special edition in Croatian: Chapter 05 Volume 007,Special edition in Slovak: Chapter 05 Volume 001,Special edition in Bulgarian: Chapter 05 Volume 002,Special edition in Maltese: Chapter 05 Volume 001,Special edition in Lithuanian: Chapter 05 Volume 001,Special edition in Polish: Chapter 05 Volume 001,Special edition in Czech: Chapter 05 Volume 001,Special edition in Slovenian: Chapter 05 Volume 001,Special edition in Hungarian: Chapter 05 Volume 001,OJ L 40, 11.2.1989,Special edition in Finnish: Chapter 15 Volume 009,Special edition in Swedish: Chapter 15 Volume 009
Effect 27-12-1988; Entry into force Date notif.
End of validity 31-12-9999
Transposition 31-12-1989; At the latest See Art 11
Notification 27-12-1988

4.

Legislative text

11.2.1989   

EN

Official Journal of the European Communities

L 40/8

 

COUNCIL DIRECTIVE

of 21 December 1988

relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems

(89/105/EEC)

THE COUNCIL OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Economic Community, and in particular Article 100a thereof,

Having regard to the proposal from the Commission (1),

In cooperation with the European Parliament (2),

Having regard to the opinion of the Economic and Social Committee (3),

Whereas marketing authorizations for proprietary medicinal products issued pursuant to Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products (4), as last amended by Directive 87/21/EEC (5), may be refused only for reasons relating to the quality, safety or efficacy of the proprietary medicinal products concerned;

Whereas Member States have adopted measures of an economic nature on the marketing of medicinal products in order to control public health expenditure on such products; whereas such measures include direct and indirect controls on the prices of medicinal products as a consequence of the inadequacy or absence of competition in the medicinal products market and limitations on the range of products covered by national health insurance systems;

Whereas the primary objective of such measures is the promotion of public health by ensuring the availability of adequate supplies of medicinal products at a reasonable cost; whereas, however, such measures should also be intended to promote efficiency in the production of medicinal products and to encourage research and development into new medicinal products, on which the maintenance of a high level of public health within the Community ultimately depends;

Whereas disparities in such measures may hinder or distort intra-Community trade in medicinal products and thereby directly affect the functioning of the common market in medicinal products;

Whereas the objective of this Directive is to obtain an overall view of national pricing arrangements, including the manner in which they operate in individual cases and all the criteria on which they are based, and to provide public access to them for all those involved in the market in medicinal products in the Member States; whereas this information should be public;

Whereas, as a first step towards the removal of these disparites, it is urgently necessary to lay down a series of requirements intended to ensure that all concerned can verify that the national measures do not constitute quantitative restrictions on imports or exports or measures having equivalent effect thereto; whereas, however, these requirements do not effect the policies of those Member States which rely primarily upon free competition to determine the price of medicinal products; whereas these requirements also do not affect national policies on price setting and on the determination of social security schemes, except as far as it is necessary to attain transparency within the meaning of this Directive;

Whereas the further harmonization of such measures must take place progressively,

HAS ADOPTED THIS DIRECTIVE:

Article 1

  • 1. 
    Member States shall ensure that any national measure, whether laid down by law, regulation or administrative action, to control the prices of medicinal products for human use or to restrict the range of medicinal products covered by their national health insurance systems complies with the requirements of this Directive.
  • 2. 
    The definition of ‘medicinal products’ laid down in Article 1 of Directive 65/65/EEC shall apply to this Directive.
  • 3. 
    Nothing in this Directive shall permit the marketing of a proprietary medicinal...

More

This text has been adopted from EUR-Lex.

5.

Original proposal

 

6.

Sources and disclaimer

For further information you may want to consult the following sources that have been used to compile this dossier:

This dossier is compiled each night drawing from aforementioned sources through automated processes. We have invested a great deal in optimising the programming underlying these processes. However, we cannot guarantee the sources we draw our information from nor the resulting dossier are without fault.

 

7.

Full version

This page is also available in a full version containing the summary of legislation, the legal context, de Europese rechtsgrond, other dossiers related to the dossier at hand and finally the related cases of the European Court of Justice.

The full version is available for registered users of the EU Monitor by ANP and PDC Informatie Architectuur.

8.

EU Monitor

The EU Monitor enables its users to keep track of the European process of lawmaking, focusing on the relevant dossiers. It automatically signals developments in your chosen topics of interest. Apologies to unregistered users, we can no longer add new users.This service will discontinue in the near future.